Registration Dossier

Diss Factsheets

Administrative data

Endpoint:
acute toxicity: other routes
Type of information:
experimental study
Adequacy of study:
other information
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Acceptable, well-documented study report which meets basic scientific principles.

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1969
Report date:
1969

Materials and methods

Principles of method if other than guideline:
other: BASF-test
GLP compliance:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
Isobutyryl chloride
EC Number:
201-194-1
EC Name:
Isobutyryl chloride
Cas Number:
79-30-1
Molecular formula:
C4H7ClO
IUPAC Name:
isobutyryl chloride
Details on test material:
- Name of test material (as cited in study report): Isobuttersäurechlorid

Test animals

Species:
mouse
Sex:
male/female

Administration / exposure

Route of administration:
intraperitoneal
Vehicle:
water
Doses:
0.25, 0.64, 0.80, 1, 1.25, 1.6, 4, 32 mg/kg bw
No. of animals per sex per dose:
10
Control animals:
not specified
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of observations: 1 hour, 1 day, 2 days, 7 days and 14 days after injection.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, gross pathology

Results and discussion

Effect levels
Sex:
male/female
Dose descriptor:
LC50
Effect level:
0.8 - 1 mg/kg bw
Based on:
test mat.
Mortality:
After 14 days:
0/20 deaths at 0.25 mg/kg bw
6/20 deaths at 0.64 mg/kg bw
4/20 deaths at 0.8 mg/kg bw
12/20 deaths at 1 mg/kg bw
16/20 deaths at 1.25 mg/kg bw
19/20 deaths at 1.67 mg/kg bw
20/20 deaths at 4 and 32 mg/kg bw
At the highest dose first deaths were observed 1 hour after administration. Over the entire dose range first deaths occurred after about 48 hours.
Clinical signs:
0.25-1.6 mg/kg bw:
directly after injection: tremble, convulsions and uncoordinated movements, extension and retardation of extremities during movement, heavy breathing, avoidance of abdominal position and fallen-in flanks. The following days: abdominal posture, apathy, closed eyes with stuck together eyelids, apnea and bristly fur. Surviving animals showed no symptoms after 3-11 days.

4 and 32 mg/kg bw:
directly after injection: jumping and stagger, heavily accelarated breathing. After about 10 minutes: abdominal position, bushy fur, closed eyes and apathy. Continuation of symptoms untill death in the following days.
Gross pathology:
Animals dying during the test: dark-blooded abdominal cavity, corosive lesions of gastrointestinal tract, slight abdominal adhesions, fatty liver (1 naimal) vessel-injected winding of small intestine.
Animals sacrificed after the observation period: adhesions in the liver area

Applicant's summary and conclusion